AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended) ~~Use of a substance for synthesising a drug for the treatment of patients who suffer from~~ A method for inhibiting maturation of dendritic cells for the treatment of a pulmonary disease which is directly or indirectly associated to idiopathic pulmonary disease, hypersensitive pneumonia or diffused panbronchilitis, ~~wherein said substance is~~ comprising administering to a patient a peptide or a polypeptide ~~containing~~ comprising the following amino acid sequence:

Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4).

2. (currently amended) ~~Use~~ The method according to claim 1, wherein said peptide or a polypeptide further ~~containing~~ comprises at least one of the following amino acid sequence:

His-Ser-Asp (SEQ ID number 14); Phe-Thr-Asp (SEQ ID NO. 13).

3. (currently amended) ~~Use~~ The method according to claim 1, wherein said peptide or a polypeptide having following amino acid sequence:

$(A)_n$-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-$(B)_m$

wherein ~~A, B is~~ $(A)_n$ and $(B)_m$ independently are primary amino acid sequences comprising any sequence of natural occurring amino ~~acid,~~ acids;n has a value from 0 to 25 and n is the number of amino acid residues in said primary amino acid sequence

$(A)_n$; and m has a value from 0 to 25 and m is the number of amino acid residues in said primary amino acid sequence $(B)_m$ ~~A and B are independent of each other; and n, m replacing values from 0-25; n and m are independent of each other~~.

4. (currently amended) ~~Use~~ The method according to claim 3, wherein if n > 2, said primary amino acid sequence $(A)_n$ further comprises a primary amino acid sequence ~~$(A)_n$ has following sequence if n > 2~~ :

$(X)_o$-Phe-Thr-Asp-$(Y)_p$;

wherein $(X)_o$ and $(Y)_p$ independently are primary amino acid sequences comprising ~~X, Y is~~ any sequence of natural occurring amino ~~acid,~~ acids; o has a value from 0 to 11 and o is the number of amino acid residues in said primary amino acid sequence $(X)_o$; and p has a value from 0 to 11 and p is the number of amino acid residues in said primary amino acid sequence $(Y)_p$ ~~X and Y are independently of each other; and o, p is a replacing value from 0-11, o and p are independent of each other~~.

5. (currently amended) ~~Use~~ The method according to claim 4, wherein if o > 2, said primary amino acid sequence $(A)_n$ further comprises a primary amino acid sequence ~~$(X)_o$ has following sequence if o > 2~~ :

$(X')_q$-His-Ser-Asp-$(X'')_r$,

wherein $(X')_q$ and $(X'')_r$ independently are primary amino acid sequences comprising ~~X', X" is~~ any sequence of natural occurring amino ~~acid,~~ acids; q has a value from 0 to 4 and q is the number of amino acid residues in said primary amino acid sequence $(X')_q$; and r has a value from 0 to 4 and r is the number of amino acid residues in said primary amino acid sequence $(X'')_r$ ~~X' and X" are independent of each other; and r, q ist a replacing value from 0-4, r and q are independent of each other~~.

6. (currently amended) ~~Use~~ The method according to claim 3, wherein the sequence of said peptide or polypetide ~~belongs to~~ is selected from the following group:

(i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4)

(ii) Phe-Thr-Asp-X^1-X^2-X^3-X^4-X^5-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 5);

(iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 6);

(iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 7);

(v) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp-X^3-X^4-X^5-X^6-X^7-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 9);

(vi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 10);

(vii) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp-Asp-X^3-X^4-X^5-X^6-X^7-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X^8-X^9-X^{10}-X^{11}-(X^{12}) (SEQ ID NO. 11);

(viii) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (VIP, SEQ ID NO. 1);

(ix) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (PACAP-38, SEQ ID NO. 2);

(x) His-Ser-Asp-X^1-X^2-Phe-Thr-Asp--X^3-X^4-X^5-X^6-X^7-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu X^8-X^9-X^{10}-X^{11}-X^{12}- X^{13}-X^{14}- X^{15}- X^{16}-X^{17}- X^{18}- X^{19}-X^{20}- X^{21}-X^{22} (SEQ ID NO. 12); and

(xi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-27, SEQ ID NO. 3);

and

wherein X^1 - X^{22} is any naturally occurring amino acid.

7. (currently amended) ~~Use~~ The method according to claim 1, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

8. (currently amended) ~~Use~~ The method according to claim 7, wherein any said peptide or polypeptide is in a stabilised form.

9. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is idiopathic pulmonary fibrosis.

10. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is hypersensitive pneumonia.

11. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is diffused panbronchiolitis.

12. (currently amended) ~~Use~~ The method according to claim 1, wherein the therapeutically effective peptides are administered as aerosols.

13. (currently amended) ~~Use~~ The method according to claim 2, wherein said disease is idiopathic pulmonary fibrosis.

14. (currently amended) ~~Use~~ The method according to claim 2, wherein said disease is hypersensitive pneumonia.

15. (currently amended) ~~Use~~ The method according to claim 2, wherein the therapeutically effective peptides are administered as aerosols.

16. (currently amended) ~~Use~~ The method according to claim 3, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

17. (currently amended) ~~Use~~ The method according to claim 3, wherein said disease is diffused panbronchiolitis.

18. (currently amended) ~~Use~~ The method according to claim 3, wherein the therapeutically effective peptides are administered as aerosols.